Apalutamide
Brand name: Erleada
Rank #50 of 500 drugs by total cost
$369.2M
Total Cost
24,956
Total Claims
$369.2M
Total Cost
888
Prescribers
$15K
Cost per Claim
1,139
Beneficiaries
25,452
30-Day Fills
$416K
Avg Cost/Provider
28
Avg Claims/Provider
About Apalutamide
Apalutamide (sold as Erleada) was prescribed 24,956 times by 888 Medicare Part D providers in 2023, costing the program $369.2M. At $15K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 47 | Macitentan (Opsumit) | $394.6M | 30,889 |
| 48 | Insulin Detemir (Levemir Flexpen) | $376.5M | 548,216 |
| 49 | Aripiprazole (Aripiprazole) | $373.1M | 1,494,971 |
| 50 | Apalutamide (Erleada) | $369.2M | 24,956 |
| 51 | Secukinumab (Cosentyx Sensoready (2 Pens)) | $347.7M | 45,496 |
| 52 | Upadacitinib (Rinvoq) | $346.0M | 51,469 |
| 53 | Abiraterone Acetate (Abiraterone Acetate) | $345.0M | 122,643 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology